Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Korean Journal of Dental Materials ; (4): 45-56, 2018.
Artículo en Inglés | WPRIM | ID: wpr-759651

RESUMEN

The purpose of this study was to evaluate the shear bond strengths between various hybrid computer-aided design (CAD)/computer-aided manufacturing (CAM) restorative materials and repairing resin. Two resin network-based hybrid (Lava Ultimate and Polyglass), one ceramic framework-based hybrid (Enamic), and one zirconia (Zenotec Zr bridge) CAD/CAM restorative materials were used in this study. The shear bond strength test and failure modes of four experimental groups designated LUS (Lava Ultimate), ENA (Enamic), PGB (Polyglass), and ZBR (zirconia control group) were characterized in this study. The hybrid CAD/CAM restorative materials showed stronger shear bond strengths in the sequence of PGB, LUS, and ENA (P < 0.05). The shear bond strengths of PGB and LUS groups showed significantly higher than those of ZBR (P < 0.05), while ENA did not show any significant difference from ZBR (P < 0.05). The PEG and LUS groups mostly exhibited cohesive failure, but the ENA and ZBR groups predominantly showed adhesive failure. Therefore, resin network-based hybrid CAD/CAM restorative materials such as Lava Ultimate and Polyglass should be more useful for intra-oral repairs.


Asunto(s)
Adhesivos , Cerámica , Resinas Compuestas , Diseño Asistido por Computadora , Prostaglandinas B
2.
Journal of the Korean Society of Magnetic Resonance in Medicine ; : 341-351, 2014.
Artículo en Coreano | WPRIM | ID: wpr-77846

RESUMEN

PURPOSE: In this study, the medication effects of Milnacipran and Pregabalin, as well known as fibromyalgia treatment medicine, in fibromyalgia syndrome patients were compared through the change of BOLD signal in pain related functional MRI. MATERIALS AND METHODS: Twenty fibromyalgia syndrome patients were enrolled in this study and they were separated into two groups according to the treatment medicine: 10 Milnacipran (MLN) treatment group and 7 Pregabalin (PGB) treatment group. For accurate diagnosis, all patients underwent several clinical tests. Pre-treated and post-treated fMRI image with block-designed pressure-pain stimulation for each group were obtained to conduct the statistical analysis of paired t-test and two sample t-test. All statistical significant level was less than 0.05. RESULTS: In clinical tests, the clinical scores of the two groups were not significantly different at pre-treatment stage. But, PGB treatment group had lower Widespread Pain Index (WPI) and Brief Fatigue Inventory (BFI) score than those of MLN treatment group at post-treatment stage. In functional image analysis, BOLD signal of PGB treatment group was higher BOLD signal at several regions including anterior cingulate and insula than MLN treatment group at post-treatment stage. Also, paired t-test values of the BOLD signal in MLN group decreased in several regions including insula and thalamus as known as 'pain network'. In contrast, size and number of regions in which the BOLD signal decreased in PGB treatment group were smaller than those of MLN treatment group. CONCLUSION: This study showed that MLN group and PGB group have different medication effects. It is not surprising that MLN and PGB have not the same therapeutic effects since these two drugs have different medicinal mechanisms such as antidepressants and anti-seizure medication, respectively, and different detailed target of fibromyalgia syndrome treatment. Therefore, it is difficult to say which medicine will work better in this study.


Asunto(s)
Humanos , Antidepresivos , Diagnóstico , Fatiga , Fibromialgia , Estudios de Seguimiento , Imagen por Resonancia Magnética , Prostaglandinas B , Tálamo , Pregabalina
3.
The Korean Journal of Pain ; : 131-136, 2011.
Artículo en Inglés | WPRIM | ID: wpr-91094

RESUMEN

BACKGROUND: Pregabalin is an anticonvulsant and analgesic agent that interacts selectively with the voltage-sensitive-Ca(2+)-channel alpha-2-delta subunit. The aim of this study was to evaluate whether the analgesic action of intrathecal (IT) pregabalin is associated with KATP channels in the rat formalin test. METHODS: IT PE-10 catheters were implanted in male Sprague-Dawley rats (250-300 g) under inhalation anesthesia using enflurane. Nociceptive behavior was defined as the number of hind paw flinches during 60 min after formalin injection. Ten min before formalin injection, IT drug treatments were divided into 3 groups: normal saline (NS) 20 microl (CON group); pregabalin 0.3, 1, 3 and 10 microg in NS 10 microl (PGB group); glibenclamide 100 microg in DMSO 5 microl with pregabalin 0.3, 1, 3 and 10 microg in NS 5 microl (GBC group). All the drugs were flushed with NS 10 microl. Immunohistochemistry for the KATP channel was done with a different set of rats divided into naive, NS and PGB groups. RESULTS: IT pregabalin dose-dependently decreased the flinching number only in phase 2 of formalin test. The log dose response curve of the GBC group shifted to the right with respect to that of the PGB group. Immunohistochemistry for the KATP channel expression on the spinal cord dorsal horn showed no difference among the groups 1 hr after the formalin test. CONCLUSIONS: The antinociceptive effect of pregabalin in the rat formalin test was associated with the activation of the KATP channel. However, pregabalin did not induce KATP channel expression in the spinal cord dorsal horn.


Asunto(s)
Animales , Humanos , Masculino , Ratas , Anestesia por Inhalación , Catéteres , Dimetilsulfóxido , Enflurano , Formaldehído , Ácido gamma-Aminobutírico , Gliburida , Cuernos , Inmunohistoquímica , Canales KATP , Dimensión del Dolor , Prostaglandinas B , Ratas Sprague-Dawley , Médula Espinal , Tienamicinas , Pregabalina
4.
Braz. j. med. biol. res ; 31(9): 1119-23, sept. 1998. ilus, graf
Artículo en Inglés | LILACS | ID: lil-222958

RESUMEN

The effect of prostaglandins (PGA1 and PGB2) on the replication of Mayaro virus was studied in Vero cells. PGA1 and PGB2 antiviral activity was found to be dose-dependent. However, while 10 µg/ml PGB2 inhibited virus yield by 60 percent, at the same dose PGA1 suppressed virus replication by more than 90 percent. SDS-PAGE analysis of [35S]-methionine-labelled proteins showed that PGA1 did not alter cellular protein synthesis. In infected cells, PGA1 slightly inhibited the synthesis of protein C, while drastically inhibiting the synthesis of glycoproteins E1 and E2


Asunto(s)
Animales , Alphavirus/fisiología , Prostaglandinas A/farmacología , Prostaglandinas B/farmacología , Células Vero/efectos de los fármacos , Replicación Viral/efectos de los fármacos , Infecciones por Alphavirus/tratamiento farmacológico , Alphavirus/efectos de los fármacos , Alphavirus/crecimiento & desarrollo , Glicoproteínas/biosíntesis , Metionina/análisis , Prostaglandinas A/metabolismo , Prostaglandinas A/uso terapéutico , Prostaglandinas B/metabolismo , Prostaglandinas B/uso terapéutico , Proteína C/biosíntesis
5.
Rev. invest. clín ; 38(3): 251-60, jul.-sept. 1986. tab, ilus
Artículo en Español | LILACS | ID: lil-104127

RESUMEN

La eficacia de la PGBx (prostaglandina derivada de la polimerización de la 15-ceto prostaglandina B1) en el tratamiento de la isquemia cerebral, fue estudiada en el modelo experimental del gervo de Mongolia, ampliamente aceptado para el estudio de la enfermedad cerebrovascular. Los gerbos fueron sometidos a 15 minutos de oclusión bilateral de la arteria carótida común. El índice de morbilidad y mortalida, la histopatología y los cambios en los metabolito de alta energía en algunas regiones cerebrales fueron comparados entre animales tratados con PGBx y aquellos sin tratamiento. Los gerbos no tratados presentaron una mortalidad del 70% siete días después de la isquemia, en cambio los que recibieron PGBx 30 minutos de la oclusión y 3 dosis adicionales con intervalo de una hora mostraron menos del 15% de mortalidad en el mismo periodo de observación. La administración de la droga 30 minutos antes no tuvo efectos en la sobrevida. Los cerebros de los animales tratados después de la isquemia presentaron mucho menor daño neuronal isquémico. La utilización de los metabolitos de alta energía en isquemia de corta duración (menos de 60 segundos) 6 horas después de la isquemia inicial, reveló que los rangos de utilización fueron más lentos en gerbos no tratados que en los tratados con PGBx. En este último grupo resultaron similares a los obtenidos en gerbos no sometidos previamente a isquemia; los presentes resultados sugieren que la PGBx tiene efectos benéficos y puede llegar a ser útil en el manejo de la enfermedad cerebrovascular isquémica en sere humanos


Asunto(s)
Animales , Masculino , Isquemia Encefálica/tratamiento farmacológico , Polímeros/uso terapéutico , Prostaglandinas B/uso terapéutico , Prostaglandinas/uso terapéutico , Isquemia Encefálica/mortalidad , Encéfalo/metabolismo , Encéfalo/patología , Gerbillinae
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA